Core Viewpoint - Jining City is implementing a comprehensive strategy for industrial economic development, focusing on the transformation and upgrading of traditional industries, the cultivation of emerging industries, and the forward-looking layout of future industries, effectively fostering new quality productive forces and achieving significant results in high-quality development [1][9][13]. Group 1: New Quality Productive Forces - New quality productive forces are defined as advanced productive forces characterized by high technology, high efficiency, and high quality, driven by innovation and aligned with new development concepts [2]. - Jining's strategy includes a "232" industrial cluster framework, forming a gradient industrial system with two trillion-level industries (new energy, high-end equipment), three hundred billion-level industries (high-end chemicals, new materials, food), and two hundred billion-level industries (new generation information technology, pharmaceuticals) [1][13]. Group 2: Economic Performance - Jining's GDP is projected to reach 586.75 billion yuan in 2024, with a year-on-year growth of 5.8%, showcasing robust economic resilience and vitality [3]. - The tertiary industry added value reached 305.54 billion yuan, growing by 6.8%, becoming the main engine for economic growth, while the secondary industry added value was 217.6 billion yuan, growing by 5.1% [3]. Group 3: Industrial Development - The industrial economy in Jining is expected to achieve high-quality development, with industrial added value reaching 185.55 billion yuan in 2024, a year-on-year increase of 6.2% [5]. - Significant projects in traditional industries include over 1,100 industrial technological transformation projects, with 249 projects included in the provincial technological transformation directory [5]. Group 4: Innovation and Market Dynamics - Jining has seen a market entity scale exceeding one million, reaching 1.016 million households, with 1,700 new "Four Up" enterprises added [7]. - The city has strengthened its innovation capabilities, with a 13% year-on-year increase in R&D expenditure and the number of high-tech enterprises reaching 1,800 [7]. Group 5: Policy Framework - Jining has introduced several policies to support the development of new quality productive forces, including plans for large-scale equipment updates and the development of the medical and health industry [9][10]. - The government emphasizes the importance of creating a modern industrial system and has set six key tasks to achieve this goal, including promoting the integration of technology and industry [10][11]. Group 6: Future Industry Layout - Jining is focusing on future industries such as aerospace, life sciences, and intelligent robotics, with plans for hydrogen energy preparation and low-altitude economy projects [19][24]. - The city aims to establish a complete innovation chain in the new energy sector, from lithium battery materials to energy storage systems, with ongoing investments in R&D [25][26].

Policy Developments - The National Health Commission is promoting the implementation of the "Blood Fee Waiver, No Need to Run Once" policy, aiming for full compliance by the end of 2025 across all blood stations and medical institutions in the country [1] Drug and Device Approvals - LuKang Pharmaceutical announced that its subsidiary has received approval for the consistency evaluation of Cimetidine Injection, which is used to treat symptoms caused by excessive stomach acid [2] - Baiyunshan reported that its subsidiary has received a drug registration certificate for Tadalafil Tablets, which are primarily used to treat erectile dysfunction [3] - Fuyuan Pharmaceutical announced that its subsidiary has received a drug registration certificate for Bromhexine Hydrochloride Oral Solution, suitable for treating respiratory diseases related to mucus secretion or clearance [4] Capital Market Activities - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor [5] - NuoTai Bio and NuoWeiZan signed a strategic cooperation agreement for a synthetic biology project, planning to establish a joint biopharmaceutical company [6] Industry Events - A medical team in the UK is experimenting with processing healthy human feces into freeze-dried powder to help patients infected with superbugs, showing promising results [8] - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, aiming to provide assessments and consultations for patients [9] - Kelong Pharmaceutical responded to accusations regarding its Ergotamine Capsules, clarifying that the product is classified as a dietary supplement rather than a drug [10] - Green Valley Pharmaceutical has halted production of the controversial drug Mannitol Sodium Capsules due to expired registration and ongoing scrutiny of its clinical trials [11] - Weili Zhibo Biotechnology has received approval from the China Securities Regulatory Commission for its IPO and the full circulation of its unlisted shares [12][14]

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-027 山东鲁抗医药股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、药品证书基本信息 近日，山东鲁抗医药股份有限公司（以下简称"公司"）控股子公司山东鲁 抗医药集团赛特有限责任公司（以下简称"赛特公司"）收到国家药品监督管理 局颁发的关于西咪替丁注射液（以下简称"该药品"）通过仿制药质量和疗效一 致性评价的《药品补充申请批准通知书》（批件号：2025B02472）。现将相关情 况公告如下： 药品名称： 西咪替丁注射液 剂型： 注射剂 胃泌素、咖啡因与胰岛素等）刺激所引起的胃酸分泌，使分泌的量和酸度均降低。 用于治疗胃酸过多引起的胃痛、胃灼热、反酸，胃及十二指肠溃疡等。 目前国内共有 40 个西咪替丁注射液生产批文。截至本公告日，共有 4 个厂家 通过或视同通过国家药品监督管理局一致性评价审批。根据药智数据显示，西咪 替丁注射液 2024 年全国医院总销售额约为 0.86 亿元。 该药品开展一致性评价工作以 ...

Core Viewpoint - The successful launch of the world's first microbial green manufacturing project for trans-aconitic acid by Qingdao Energy Research Institute and Shandong Lukang Pharmaceutical Co., Ltd. marks a significant breakthrough in the accessibility of this important chemical raw material, which will effectively promote the rapid development of downstream applications such as bio-based materials and biopesticides [1][3]. Group 1: Project Overview - The project was officially launched on May 29, 2024, in Jining, Shandong, and is recognized for overcoming the challenges in microbial green manufacturing technology for trans-aconitic acid [1][3]. - The technology has been evaluated as internationally leading, with strong innovation and advanced indicators, suggesting further expansion of production and application scale [3][4]. Group 2: Technological Innovations - The project utilizes synthetic biology strategies to achieve microbial green manufacturing of trans-aconitic acid for the first time, employing high acid-resistant Aspergillus niger as the chassis cell [3][4]. - Key technological developments include enabling technology platforms, efficient cell factories, fermentation process demonstration, and separation and purification processes, leading to the establishment of the world's first demonstration line for microbial green manufacturing of trans-aconitic acid [3][4]. Group 3: Industry Impact - The collaboration between Qingdao Energy Research Institute and Lukang Pharmaceutical exemplifies interdisciplinary innovation in bio-chemical-materials integration, transforming disruptive technologies into new productive forces [4]. - The project has been recognized as a benchmark for green, low-carbon, and high-quality development, injecting new momentum into the bio-economy sector [5].

Core Viewpoint - The successful launch of the world's first microbial green manufacturing project for trans-aconitic acid by Qingdao Energy Institute and Shandong Lukang Pharmaceutical marks a significant breakthrough in the accessibility of this important chemical raw material, which will effectively promote the rapid development of downstream applications such as bio-based materials and biopesticides [1][3]. Group 1: Project Overview - The project was officially launched on May 29 in Jining, Shandong, and represents a major advancement in the microbial green manufacturing technology for trans-aconitic acid [1]. - The technology has been recognized as internationally leading, having overcome challenges in microbial green manufacturing, and has established the world's first demonstration line for this production method [3][4]. Group 2: Technological Innovations - The project utilized a high acid-resistant strain of Aspergillus niger as the chassis cell and developed key technologies including enabling technology platforms, efficient cell factories, fermentation process demonstration, and separation and purification processes [3]. - The successful scale-up of fermentation processes was achieved at a pilot level of ten tons, demonstrating the feasibility of large-scale production [3]. Group 3: Applications and Impact - The project has led to the development of environmentally friendly, safe, and economical new bio-based plasticizers derived from trans-aconitic acid, providing innovative solutions for sectors such as medical devices, electrical cables, and specialty rubber [4]. - The project has been awarded the highest prize at the first National Disruptive Technology Innovation Competition, showcasing its potential to lead industry innovation through technology [5].

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

化学制药板块短线拉升，海南海药（000566）、华海药业（600521）涨停，天宇股份（300702）涨超 10%，金城医药（300233）、赛托生物（300583）、微芯生物、鲁抗医药（600789）、纳微科技等跟 涨。 暗盘资金一眼洞悉庄家意图>> ...

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 猪肉 | 2.39 | 可控核聚变 | -3.47 | | 养鸡 | 1.94 | 减速器 | -3.18 | | 创新药 | 1.56 | EDR概念 | -3.01 | | 动物疫苗 | 1.35 | 人形机器人 | -2.90 | | 眼科医疗 | 1.30 | 一体化压铸 | -2.79 | | 细胞免疫治疗 | 1.25 | 汽车热管理 | -2.63 | | 青蒿素 | 1.17 | 无线充电 | -2.51 | | 仿制药一致性评价 | 1.16 | 铜缆高速连接 | -2.49 | | 重组蛋白 | 1.11 | 拼多多概念 | -2.48 | | 生物疫苗 | 1.01 | 智能座舱 | -2.48 | 资金面上看，今日仿制药一致性评价概念板块获主力资金净流入4.35亿元，其中，63股获主力资金净流 入，6股主力资金净流入超5000万元，净流入资金居首的是千红制药，今日主力资金净流入2.20亿元， 净流入资金居前的还有海南海药、哈三联、鲁抗医药 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-026 山东鲁抗医药股份有限公司 关于子公司药品通过仿制药一致性评价的公告 剂型： 片剂 规格：0.25g（按 C38H72N2O12计） 原药品批准文号：国药准字 H20033298 药品注册标准编号：YBH12372025 注册分类：化学药品 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，山东鲁抗医药股份有限公司（以下简称"公司"）控股子公司山东鲁 抗医药集团赛特有限责任公司（以下简称"赛特公司"） 收到国家药品监督管理 局颁发的关于阿奇霉素片（以下简称"该药品"）通过仿制药质量和疗效一致性 评价的《药品补充申请批准通知书》（批件号：2025B02344）。现将相关情况公 告如下： 一、药品证书基本信息 药品名称： 阿奇霉素片 三、对公司的影响及风险提示 赛特公司阿奇霉素片通过一致性评价，有效提升了该药品的市场竞争力，有 利于增加市场销量，同时为后续产品开展仿制药一致性评价工作积累了有益的经 验。药品的生产和销售容易受国家政策、市场环境等诸多因素的影响 ...

1. Report Industry Investment Rating - No relevant content provided. 2. Core Viewpoints of the Report - The report analyzes Shandong provincial state - owned capital investment and operation companies from four dimensions: establishment background and process, positioning and consolidated business directions, assets and profitability, and outstanding bonds and bond valuations [2]. - Shandong provincial state - owned capital investment and operation companies' construction process can be divided into three stages: transferring state - owned capital to the provincial social security fund (2014 - 2017), introducing Shandong Guohui and transferring 20% of social security funds to it (2018 - 2020), and restructuring the social security fund council into Caixin Company and reorganizing the provincial investment and operation platforms (2020 - present) [2][8][9]. - These companies can be classified into five types according to their functions and business directions: state - owned capital operation companies, diversified industrial investment companies, focused industrial investment companies, financial investment companies, and policy - oriented investment companies [3][15]. - The asset scale of 12 provincial state - owned capital investment and operation companies in Shandong is significantly differentiated, and the asset structure varies greatly due to different functional positioning and business segments. Their profitability is good but has been under pressure in recent years [4][31][43]. - The outstanding bonds are mainly public bonds, and the scale is also significantly differentiated. Shandong Development, Shandong Guotou, Shandong Land, Shandong Steel Group, and Shandong High - speed have relatively low weighted ChinaBond valuation yields [5][52]. 3. Summary According to the Directory 3.1 Emergence: Establishment of Shandong Provincial Investment and Operation Companies - In 2013, the Third Plenary Session of the 18th Central Committee proposed to reform the state - owned capital authorization and operation system. Shandong Province launched a new round of state - owned enterprise reform [6]. - In 2014, Shandong issued the "26 Articles on Shandong State - owned Enterprise Reform", and in 2015, it passed the "1 + 5" documents, which jointly formed the top - level design for the construction of Shandong's state - owned investment and operation platforms [7]. - The construction process of Shandong provincial state - owned capital investment and operation companies has three stages: transferring state - owned capital to the social security fund, introducing Shandong Guohui, and restructuring and integrating platforms [2][8][9]. 3.2 Anchoring Direction: Company Positioning and Consolidated Business Directions - Companies are divided into five types: state - owned capital operation companies (e.g., Shandong Guotou), diversified industrial investment companies (e.g., Hualu Group, Lushang Group, Shandong Guohui), focused industrial investment companies (e.g., Shandong Energy, Shandong Gold, Shandong High - speed, Shandong Steel Group), financial investment companies (e.g., Luxin Group), and policy - oriented investment companies (e.g., Shandong Land, Shandong Development, Shandong Finance) [3][15]. - Each type of company has its own core business and development strategy. For example, Shandong Guotou focuses on IT business, Hualu Group on high - end chemical industry, and Luxin Group on financial services [19][20][23]. 3.3 Financial Perspective: Company Assets and Profitability 3.3.1 Asset Dimension - Asset scale is significantly differentiated, divided into four echelons. Shandong High - speed and Shandong Energy have over - trillion - yuan asset scales, while Shandong Development has the smallest scale [31]. - Asset composition varies. There are four types based on the consolidated statements: assets mainly formed by industrial subsidiaries' businesses, financial assets and long - term equity investments in financial subsidiaries, assets mainly formed by equity investments, and assets mainly formed by government - function infrastructure and its investment and financing services [32][34][35]. 3.3.2 Profitability Dimension - The overall profitability of 12 companies is good but has been under pressure in recent years. Since 2022, the overall revenue growth has slowed down, and the net profit has declined [43]. - In terms of revenue structure, 7 companies have more retained operating profits, 4 companies' profits mainly come from investment income, and Shandong Steel's investment income is an important source of profit due to industry downturn [44]. 3.4 Bond Market: Outstanding Bonds and Bond Valuation Overview - Outstanding bonds are mainly public bonds, and the scale is significantly differentiated. Shandong High - speed has the highest outstanding bond scale, while Shandong Development and Hualu Group have the smallest [52]. - Shandong Development, Shandong Guotou, Shandong Land, Shandong Steel Group, and Shandong High - speed have relatively low weighted ChinaBond valuation yields, less than 2% [52].